目的 :建立西沙必利血药浓度的HPLC测定方法。方法 :血浆样品经氢氧化钠碱化后用正庚烷 异戊醇提取 ,有机相经氮气吹干后用流动相溶解进样。分析柱 μ BondapakODS柱 ( 3 9mm× 30 0mm ,10 μm ) ;流动相为0 0 2mol·L 1磷酸盐缓冲液 乙腈 ( 47:5 3 ,V/V ,pH7 0 ) ,流速 1 4ml·min 1;检测波长 2 76nm。结果 :线性范围为0 78～ 2 0 0 μg·L 1(r =0 .9998) ,日内和日间精密度小于 6 %。结论 :体内过程符合口服吸收二室模型 ,Cmax=( 88 2 0± 12 2 0 ) μg·L 1,Tpeak=( 1 91± 0 2 2 )h ,t1/ 2 β=( 11 0± 2 77)h ,AUC =( 6 86 5 7± 10 9 16 ) μg·h·L 1。 Objective: To establish a HPLC method for the determination of cisapride plasma concentration. Methods: The plasma samples were alkalinized with sodium hydroxide and extracted with n-heptane isoamyl alcohol. The organic phase was dried with nitrogen and dissolved in mobile phase. Analytical column μ BondapakODS column (39 mm × 30 0 mm, 10 μm); mobile phase was 0 2mol·L -1 phosphate buffer (47:53, V / V, pH 7.0) ; Detection wavelength of 2 76nm. Results: The linear range was 0 78 ~ 200 μg · L 1 (r = 0.9998). The intra- and inter-day precision was less than 6%. CONCLUSIONS: The in vivo process is consistent with the two-compartment model of oral absorption with Cmax = (88 2 0 ± 12 2 0) μg · L 1, Tpeak = (1 91 ± 0 2 2) h, t1 / 2 β = (11 0 ± 2 77 ) h, AUC = (6 86 57 ± 10 9 16) μg · h · L 1.